JP7352539B2 - 免疫療法に対する腫瘍応答およびその毒性を予測するためのバイオマーカー - Google Patents

免疫療法に対する腫瘍応答およびその毒性を予測するためのバイオマーカー Download PDF

Info

Publication number
JP7352539B2
JP7352539B2 JP2020519012A JP2020519012A JP7352539B2 JP 7352539 B2 JP7352539 B2 JP 7352539B2 JP 2020519012 A JP2020519012 A JP 2020519012A JP 2020519012 A JP2020519012 A JP 2020519012A JP 7352539 B2 JP7352539 B2 JP 7352539B2
Authority
JP
Japan
Prior art keywords
cancer
patient
nucleotide
seq
position corresponding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020519012A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020524180A (ja
JP2020524180A5 (enExample
Inventor
ジョアン ウェイダース，
Original Assignee
ミラディーエックス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ミラディーエックス filed Critical ミラディーエックス
Publication of JP2020524180A publication Critical patent/JP2020524180A/ja
Publication of JP2020524180A5 publication Critical patent/JP2020524180A5/ja
Priority to JP2023149977A priority Critical patent/JP7773014B2/ja
Application granted granted Critical
Publication of JP7352539B2 publication Critical patent/JP7352539B2/ja
Priority to JP2025167674A priority patent/JP2025188113A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1077—Beam delivery systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Radiology & Medical Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2020519012A 2017-06-15 2018-06-15 免疫療法に対する腫瘍応答およびその毒性を予測するためのバイオマーカー Active JP7352539B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023149977A JP7773014B2 (ja) 2017-06-15 2023-09-15 免疫療法に対する腫瘍応答およびその毒性を予測するためのバイオマーカー
JP2025167674A JP2025188113A (ja) 2017-06-15 2025-10-03 免疫療法に対する腫瘍応答およびその毒性を予測するためのバイオマーカー

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762520459P 2017-06-15 2017-06-15
US62/520,459 2017-06-15
PCT/US2018/037866 WO2018232313A2 (en) 2017-06-15 2018-06-15 Biomarkers for predicting tumor response to and toxicity of immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023149977A Division JP7773014B2 (ja) 2017-06-15 2023-09-15 免疫療法に対する腫瘍応答およびその毒性を予測するためのバイオマーカー

Publications (3)

Publication Number Publication Date
JP2020524180A JP2020524180A (ja) 2020-08-13
JP2020524180A5 JP2020524180A5 (enExample) 2021-07-29
JP7352539B2 true JP7352539B2 (ja) 2023-09-28

Family

ID=64659596

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020519012A Active JP7352539B2 (ja) 2017-06-15 2018-06-15 免疫療法に対する腫瘍応答およびその毒性を予測するためのバイオマーカー
JP2023149977A Active JP7773014B2 (ja) 2017-06-15 2023-09-15 免疫療法に対する腫瘍応答およびその毒性を予測するためのバイオマーカー
JP2025167674A Pending JP2025188113A (ja) 2017-06-15 2025-10-03 免疫療法に対する腫瘍応答およびその毒性を予測するためのバイオマーカー

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023149977A Active JP7773014B2 (ja) 2017-06-15 2023-09-15 免疫療法に対する腫瘍応答およびその毒性を予測するためのバイオマーカー
JP2025167674A Pending JP2025188113A (ja) 2017-06-15 2025-10-03 免疫療法に対する腫瘍応答およびその毒性を予測するためのバイオマーカー

Country Status (6)

Country Link
US (3) US11578371B2 (enExample)
EP (2) EP3638308B1 (enExample)
JP (3) JP7352539B2 (enExample)
AU (2) AU2018283314B2 (enExample)
CA (1) CA3067366A1 (enExample)
WO (1) WO2018232313A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230103419A1 (en) * 2020-02-12 2023-04-06 Mira Dx, Inc. Biomarkers for predicting toxicity of radiation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060253263A1 (en) 2005-04-11 2006-11-09 Meshkin Brian J Method to optimize drug selection, dosing and evaluation and to help predict therapeutic response and toxicity from immunosuppressant therapy

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4988167A (en) 1988-08-10 1991-01-29 Fergason James L Light blocking and vision restoration apparatus with glint control
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
US20030087818A1 (en) * 2001-02-02 2003-05-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US10471100B2 (en) 2006-09-29 2019-11-12 4Life Patents, Llc Nanofraction immune modulators, preparations and compositions including the same, and associated methods
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2011131472A1 (en) * 2010-04-22 2011-10-27 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
EP2850183A4 (en) 2012-05-16 2016-02-10 Rana Therapeutics Inc COMPOSITIONS AND METHOD FOR MODULATING GENE EXPRESSION
WO2014193937A1 (en) * 2013-05-31 2014-12-04 Yale University The kras variant and response to cancer therapy
US20170115291A1 (en) * 2014-05-28 2017-04-27 Dana-Farber Cancer Institute, Inc. Activating JAK Kinase Biomarkers Predictive of Anti-Immune Checkpoint Inhibitor Response
US10392442B2 (en) * 2015-12-17 2019-08-27 Bristol-Myers Squibb Company Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
EP3449015A1 (en) * 2016-04-27 2019-03-06 Mira DX, Inc. Immune-based treatment of kras-variant cancer patients

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060253263A1 (en) 2005-04-11 2006-11-09 Meshkin Brian J Method to optimize drug selection, dosing and evaluation and to help predict therapeutic response and toxicity from immunosuppressant therapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Annals of Oncology，2016年，Vol.27，pp.1199-1206
Pigment Cell Melanoma Res.，2015年，Vol.28，pp.590-598
PLoS ONE，2016年，Vol.11，e0148270

Also Published As

Publication number Publication date
EP3638308A2 (en) 2020-04-22
US11578371B2 (en) 2023-02-14
AU2025223839A1 (en) 2025-09-18
JP2020524180A (ja) 2020-08-13
JP2025188113A (ja) 2025-12-25
WO2018232313A2 (en) 2018-12-20
US20240132966A1 (en) 2024-04-25
US20250305062A1 (en) 2025-10-02
JP2023161032A (ja) 2023-11-02
JP7773014B2 (ja) 2025-11-19
WO2018232313A3 (en) 2019-02-21
AU2018283314A1 (en) 2020-01-16
EP3638308C0 (en) 2024-08-28
EP3638308A4 (en) 2021-06-16
EP4491746A3 (en) 2025-07-09
US20210147941A1 (en) 2021-05-20
CA3067366A1 (en) 2018-12-20
EP3638308B1 (en) 2024-08-28
US12297509B2 (en) 2025-05-13
EP4491746A2 (en) 2025-01-15
AU2018283314B2 (en) 2025-05-29

Similar Documents

Publication Publication Date Title
ES2953595T3 (es) Procedimientos diagnósticos y terapéuticos para el cáncer
US12466888B2 (en) Methods of treating tumor
US20240410016A1 (en) Cd274 rearrangements as predictors of response to immune checkpoint inhibitor therapy
WO2019178217A1 (en) Methods and compositions for treating, diagnosing, and prognosing cancer
CN112912403A (zh) 治疗肿瘤的方法
CN113396230A (zh) 癌症的诊断和治疗方法
JP2025188113A (ja) 免疫療法に対する腫瘍応答およびその毒性を予測するためのバイオマーカー
WO2022147163A1 (en) Alk fusion genes and uses thereof
US20250129429A1 (en) Gene fusions in sarcoma
US20240410018A1 (en) Novel kinase fusions detected by liquid biopsy
US20240263240A1 (en) Cd274 mutations for cancer treatment
AU2022234761A1 (en) Methods for the treatment of cancer
AU2024371732A1 (en) Monitoring circulating tumor dna (ctdna)
JP2024516230A (ja) がんのための治療及び診断方法並びに組成物
US20260132471A1 (en) Genomic biomarkers of early recurrence in colorectal cancer (crc)
US20250149116A1 (en) Abl1 fusions and uses thereof
WO2024238675A2 (en) Genomic biomarkers of early recurrence in colorectal cancer (crc)
HK40055955A (en) Diagnostic and therapeutic methods for cancer
WO2024168146A1 (en) Braf gene fusions and uses thereof
EP4532025A1 (en) Igf1r activation mutations and uses thereof
Cummin et al. 09 Diffuse Large B Cell Lymphoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210615

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210615

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221012

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230123

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230421

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230724

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230816

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230915

R150 Certificate of patent or registration of utility model

Ref document number: 7352539

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350